<DOC>
	<DOCNO>NCT00538980</DOCNO>
	<brief_summary>The purpose conduct research study determine feasibility use dasatinib treatment polycythemia vera determine optimum treatment regimen .</brief_summary>
	<brief_title>Dasatinib Polycythemia Vera</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients must &gt; = 18 year old 2 . Performance Status ( ECOG ) 03 3 . Previous therapy limit interferonalpha , hydroxyurea , anagrelide , imatinib 4 . Patients may document resistance intolerance interferonalpha , imatinib , hydroxyurea , anagrelide , must demonstrate phlebotomy dependent require 6 phlebotomy per year maintain target HCT . 5 . Patients may newly diagnose PV . 6 . Patients may inadequate phlebotomy control hydroxyurea imatinib . 7 . Adequate Organ Function Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ( ULN ) Hepatic enzyme ( AST , ALT ) ≤ 2.5 time institutional ULN Serum Na , K+ , Mg2+ , Phosphate Ca2+³ Lower Limit Normal ( LLN ) Serum Creatinine &lt; 1.5 time institutional ULN Hemoglobin , Neutrophil count , Platelets , PT , PTT Grade 01 8 . Ability take oral medication : dasatinib tablet may swallow whole , may ingest solution . Dasatinib tablets dissolved juice , administer nasogastric tube . 9 . Women childbearing potential ( WOCBP ) must : A negative serum urine pregnancy test within 72 hour prior start study drug administration 10 . Persons reproductive potential must agree use adequate method contraception throughout treatment least 4 week study drug stop . 11 . Signed write informed consent include HIPAA accord institutional guideline 1 . Patients receive busulfan within six week Study Day 1 . 2 . Patients receive treatment interferonalpha within 4 week Study Day 1 . 3 . Patients receive treatment imatinib within 14 day Study , Day 1 . 4 . Patients Grade 3 4 cardiac problem define New York Heart Association Criteria . 5 . Patients history noncompliance medical regimen consider potentially unreliable . 6 . A malignancy [ one treat study ] , require radiotherapy systemic treatment within past 5 year . 7 . Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade Clinicallysignificant coagulation platelet function disorder ( e.g . know von Willebrand 's disease ) 8 . Cardiac Symptoms , consider follow : Uncontrolled angina , congestive heart failure MI within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Subjects hypokalemia hypomagnesemia correct 9 . History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) Ongoing recent ( ≤ 3 month ) significant gastrointestinal bleeding 10 . Concomitant Medications , consider follow prohibition : Drugs generally expect risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) The concomitant use H2 blocker proton pump inhibitor dasatinib recommend . The use antacid consider place H2 blocker proton pump inhibitor patient receive dasatinib therapy . Patient agree discontinue St. Johns Wort receive dasatinib therapy Patient agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . Patient may receive prohibited CYP3A4 inhibitor 11 . Women : Unwilling unable use acceptable method avoid pregnancy entire study period least 4 week cessation study drug , Have positive pregnancy test baseline , Are pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Polycythemia Vera</keyword>
	<keyword>PV</keyword>
	<keyword>P Vera</keyword>
</DOC>